About 1 million people are living with multiple sclerosis in the U.S. alone with millions of other cases around the world so a huge effort has gone into trying to find new approaches to the disease including stem cells for MS. We’ll start our weekly recommended reads by talking about a new paper on MS […]
Stem cells for MS & other weekly reads: CRISPR, COVID & a bat cave, Huntington’s Read More »
Another busy week including on the grant writing treadmill or should I say Mobius strip, but I’m always on the lookout for new reading and this week a lot popped up on regeneration. Also, a paper on healing and scarring. I regularly write about stem cell journals. For a long time, it seems like Cell Stem
Stem cell reads: regeneration, 8C, MYC, CRISPR babies Read More »
The idea of stem cells outright curing diseases is exciting and has powerful appeal, but media need to be careful about using the word cure in headlines and articles as we saw this week related to a possible HIV Cure. HIV cure via stem cells and chemo? The big news of the week was that
Weekly reads: possible rare HIV cure, stem cell chicken, FDA commish Read More »
Is 2022 going to be any better than 2020 or 2021 when it comes to things in general or for biomedical science? Related to the pandemic? It’s too soon to say but if I had to guess right now I’d venture an optimistic view that overall it’s going to be somewhat better by the end
Weekly science reads: senescence, alt CRISPR, sickle cell update Read More »
When I read about Elizabeth Holmes and her blood testing startup Theranos I see parallels to hucksters in the arena of stem cells and cell therapy. I’m thinking especially of the unproven stem cell clinics out there. It goes farther than that though too, including people who aren’t hucksters at all but get caught up
Elizabeth Holmes, Theranos, & lessons for the stem cell field Read More »
The last few years in the stem cell and regenerative medicine arena have been complicated in many ways. Variables like surging stem cell clinics and COVID have made predictions harder. Even so, trying to make predictions is useful and it’s fun to go over past year’s predictions. You can see my scorecard on my 2021
16 predictions for stem cells & regenerative medicine in 2022 Read More »
The past year was all over the place for the stem cell and regenerative medicine field. As you can see in my scoring of my 21 predictions for 2021, quite a few things were surprises in terms of what did and didn’t happen. Here’s an overview of the top stories of the year in our
Top stem cell stories of 2021: COVID, diabetes, human embryos, clinics in court Read More »
The world of stem cell research and regenerative medicine is unpredictable but it’s fun to be a part of it and try to do predictions. Each year in late December or early January I make prognostications for the coming year for stem cell research and regenerative medicine. I made 21 such predictions for the current
Grading my 21 stem cell & regenerative medicine predictions for 2021 Read More »
A quick review of the publicly-traded stem cell stocks I’ve been following in 2021 finds mostly discouraging news, but a few firms relatively outperformed the other publically-traded biotechs. One had some great news today. In this post, I’m doing a brief overview of how things went this year in the regenerative medicine space. I’m going
2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best Read More »
Part of being a grad student is dealing with technologies related to your projects and their limitations. Sometimes I feel old when I remember the way we used to have to do things in the lab. As a grad student, I manually poured, ran, and read giant sequencing gels. Back then, gene synthesis of a
Weekly reads: grad student life, cell barcoding, diabetes trial, more Read More »